CLINICAL TRIALS PROFILE FOR RISPERDAL
✉ Email this page to a colleague
505(b)(2) Clinical Trials for RISPERDAL
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT01770600 ↗ | Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression | Withdrawn | University of Alabama at Birmingham | N/A | 2010-04-01 | This study is dedicated to achieving a better understanding of how the brain processes information. Specifically, the investigators are studying cognitive function, thought process, and impulsivity in people with and without suicidal thoughts. You are being asked to participate in a research study to learn how the use of a medication, risperidone, improves your symptoms of depression. Specifically the investigators are studying the effectiveness of reducing the thought of suicide and other symptoms of severe depression. Risperidone is approved by FDA for the treatment of schizophrenia and bipolar mania, and clinical practice suggests that it might benefit patients with major depressive disorder. During clinical trials with 2607 patients, risperidone was proved to be safe. This is a pilot study to test a new indication of risperidone for treatment of severe depression. The study medication will be given in addition to usual psychiatric care. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for RISPERDAL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000374 ↗ | Treatment for First-Episode Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 1998-09-01 | This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia. |
| NCT00000374 ↗ | Treatment for First-Episode Schizophrenia | Completed | The Zucker Hillside Hospital | Phase 4 | 1998-09-01 | This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia. |
| NCT00000374 ↗ | Treatment for First-Episode Schizophrenia | Completed | Northwell Health | Phase 4 | 1998-09-01 | This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia. |
| NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RISPERDAL
Condition Name
Clinical Trial Locations for RISPERDAL
Trials by Country
Clinical Trial Progress for RISPERDAL
Clinical Trial Phase
Clinical Trial Sponsors for RISPERDAL
Sponsor Name
